Foxo Technologies Inc. (FOXO) intrinsic value & 10-year financials

Foxo Technologies Inc. (FOXO) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 6 fiscal years revenue grew 241.7% a year to $16.4M, with an average return on invested capital of 1114.8%.

Graham intrinsic value
—
Share price (Oct 17, 2026)
$0.11
Revenue (FY2025)
$16.4M
Revenue growth (6-yr CAGR)
241.7%
ROIC (10-yr avg)
1114.8%
Free cash flow (FY2025)
-$3.9M

FOXO 10-year financial history

Fiscal year Revenue Net income EPS (diluted) Free cash flow Operating margin ROIC
FY2025 $16.4M -$12.4M — -$3.9M -63.1% -88.4%
FY2024 $4.1M -$12.4M — — -191.6% -139.0%
FY2023 $145.3K -$26.5M — — -15271.4% 715.7%
FY2022 $511.0K -$95.3M — -$23.9M -7860.5% 3914.7%
FY2021 $120.0K -$38.5M — -$897.3K -12525.8% 1170.8%
FY2020 — — — — — —

Source: annual 10-K filings on SEC EDGAR. Figures in USD.

Executive summary

FOXO TECHNOLOGIES INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.

FOXO TECHNOLOGIES INC. has historically struggled to out-earn its cost of capital, averaging just -33.9% ROIC.

FOXO TECHNOLOGIES INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.

Benjamin Graham lens

Under Benjamin Graham's formula using SEC EDGAR fundamentals, FOXO TECHNOLOGIES INC. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment.

FOXO stock: frequently asked questions

Does Foxo Technologies Inc. generate free cash flow?

Foxo Technologies Inc. generated -$3.9M of free cash flow (operating cash flow minus capital expenditures) in fiscal 2025. Free cash flow was positive in 0 of the last 3 reported years.

What is FOXO's return on invested capital?

Average ROIC over the last 6 fiscal years was 1114.8%, and average return on equity was 1186.6%. Sustained ROIC above about 15% usually points to a durable competitive advantage.

Where does this FOXO data come from?

From Foxo Technologies Inc.'s annual 10-K filings on SEC EDGAR, most recently filed May 15, 2026. Prices are end-of-day snapshots; valuations are formula outputs, not investment advice.

Similar commercial physical & biological research stocks